Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity

(2017) Xiaoxin X. Wang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pathology of non-alcoholic fatty liver disease

(2017) Pierre Bedossa   LIVER INTERNATIONAL

Non-alcoholic fatty liver disease: A sign of systemic disease

(2017) Isabella Reccia et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Induction of Steatohepatitis (NASH) with Insulin Resistance in Wild-type B6 Mice by a Western-type Diet Containing Soybean Oil and Cholesterol

(2017) Janin Henkel et al.   MOLECULAR MEDICINE

Targeting nuclear receptors for the treatment of fatty liver disease

(2017) Naoki Tanaka et al.   PHARMACOLOGY & THERAPEUTICS

Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation

(2017) Da-Gang Zhang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

(2017) Hani Jouihan et al.   Molecular Metabolism

GLP-1 and weight loss: unraveling the diverse neural circuitry

(2016) Scott E. Kanoski et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

(2016) S. J. Henderson et al.   DIABETES OBESITY & METABOLISM

Obeticholic Acid: First Global Approval

(2016) A. Markham et al.   DRUGS

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

(2016) Yaron Rotman et al.   GUT

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

(2016) Amon Asgharpour et al.   JOURNAL OF HEPATOLOGY

C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis

(2016) Khalidur Rahman et al.   LABORATORY INVESTIGATION

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice

(2016) Fahrettin Haczeyni et al.   Obesity

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis

(2015) Niraj S. Patel et al.   Clinical Gastroenterology and Hepatology

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

(2015) Arun J. Sanyal et al.   HEPATOLOGY

Bile acids: emerging role in management of liver diseases

(2015) Amon Asgharpour et al.   Hepatology International

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice

(2015) Tamiris Lima Rachid et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Liraglutide: A New Option for the Treatment of Obesity

(2015) Wesley A. Nuffer et al.   PHARMACOTHERAPY

The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects

(2014) Rémy Hanf et al.   Diabetes & Vascular Disease Research

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

(2014) Michal Pawlak et al.   HEPATOLOGY

Beyond intestinal soap—bile acids in metabolic control

(2014) Folkert Kuipers et al.   Nature Reviews Endocrinology

Overactivation of Intestinal SREBP2 in Mice Increases Serum Cholesterol

(2014) Ke Ma et al.   PLoS One

Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology

(2014) Wen Liang et al.   PLoS One

Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment

(2013) Jason R. Clapper et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Bile acid receptors in non-alcoholic fatty liver disease

(2013) Yuanyuan Li et al.   BIOCHEMICAL PHARMACOLOGY

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

Immune and inflammatory pathways in NASH

(2013) Michal Ganz et al.   Hepatology International

Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

(2013) Rachel H. McMahan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype

(2013) Geoffrey C. Farrell et al.   LIVER INTERNATIONAL

Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance

(2013) Yongjie Ma et al.   PHARMACEUTICAL RESEARCH

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

A position statement on NAFLD/NASH based on the EASL 2009 special conference

(2010) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Liraglutide

(2010) Daniel J. Drucker et al.   NATURE REVIEWS DRUG DISCOVERY

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

(2009) Stefano Fiorucci et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent

(2008) Laura H. Tetri et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet

(2008) B. Kong et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators

(2007) Frank J. Gonzalez et al.   TOXICOLOGY